MPO and colitis: At the end of a 3 wk feeding trial, DSS-treated SAMP mice given C:15 prior to DSS at either 1X (26 μg/mouse/day) or 2X (52 μg/mouse/day) dosages exhibited reduced severity of DSS colitis (body weight, colon length, histology, fecal MPO; Figure S1), with lower colonoscopy mean scores by the end of the 7-day DSS-treatment cycle [C:15(1X): 1.6 ± 0.8, C:15(2X): 1.6 ± 0.8 vs. control: 4.7 ± 0.9, ANOVA P = 0.03], as well as had improved gut permeability (i.e., less translocation of FITC-dextran from the gut lumen into the plasma), compared with controls (Figure S1).